Invion Ltd. (AU:IVX) has released an update.
Invion Limited is at the forefront of developing Photosoft™ technology, a next-generation Photodynamic Therapy (PDT) for treating various cancers, atherosclerosis, and infectious diseases. The technology, licensed for use in multiple regions excluding some Asia Pacific countries and others, is currently undergoing research and clinical trials funded by RMW Cho Group Limited. Invion’s innovative approach to PDT offers a less invasive option with minimal side effects, providing hope against antibiotic-resistant pathogens and aiming for complete tumor regression.
For further insights into AU:IVX stock, check out TipRanks’ Stock Analysis page.
